Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
32.98
+0.30 (0.92%)
Jul 10, 2025, 4:00 PM - Market closed
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Xenon Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $54.82, which forecasts a 66.22% increase in the stock price over the next year. The lowest target is $47 and the highest is $67.
Price Target: $54.82 (+66.22%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 14, 2025.
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $55 | Buy | Initiates | $55 | +66.77% | May 14, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $47 | Buy | Maintains | $50 → $47 | +42.51% | May 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $58 → $55 | Buy | Maintains | $58 → $55 | +66.77% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +60.70% | May 13, 2025 |
| Needham | Needham | Strong Buy Maintains $60 → $55 | Strong Buy | Maintains | $60 → $55 | +66.77% | May 13, 2025 |
Financial Forecast
Revenue This Year
7.14M
Revenue Next Year
25.26M
from 7.14M
Increased by 253.71%
EPS This Year
-4.10
from -3.01
EPS Next Year
-4.48
from -4.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.4M | 210.0M | 295.0M | ||
| Avg | 7.1M | 25.3M | 97.3M | ||
| Low | n/a | n/a | 18.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,841.2% | 1,068.0% | ||
| Avg | - | 253.7% | 285.3% | ||
| Low | - | - | -26.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.60 | -2.15 | -1.12 | ||
| Avg | -4.10 | -4.48 | -4.48 | ||
| Low | -4.39 | -5.63 | -5.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.